001     277315
005     20250323000915.0
024 7 _ |a 10.1126/scisignal.adl6745
|2 doi
024 7 _ |a pmid:39999211
|2 pmid
024 7 _ |a 1945-0877
|2 ISSN
024 7 _ |a 1937-9145
|2 ISSN
024 7 _ |a altmetric:174524171
|2 altmetric
037 _ _ |a DZNE-2025-00378
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Sona, Chandan
|0 0000-0003-3107-016X
|b 0
245 _ _ |a Glutamatergic argonaute2 promotes the formation of the neurovascular unit in mice.
260 _ _ |a Washington, DC [u.a.]
|c 2025
|b Assoc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742214654_23586
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Proper formation of the complex neurovascular unit (NVU) along with the blood-brain barrier is critical for building and sustaining a healthy, functioning central nervous system. The RNA binding protein argonaute2 (Ago2) mediates microRNA (miRNA)-mediated gene silencing, which is critical for many facets of brain development, including NVU development. Here, we found that Ago2 in glutamatergic neurons was critical for NVU formation in the developing cortices of mice. Glutamatergic neuron-specific loss of Ago2 diminished synaptic formation, neuronal-to-endothelial cell contacts, and morphogenesis of the brain vasculature, ultimately compromising the integrity of the blood-brain barrier. Ago2 facilitated miRNA targeting of phosphatase and tensin homolog (Pten) mRNA, which encodes a phosphatase that modulates reelin-dependent phosphatidylinositol 3-kinase (PI3K)-Akt signaling within the glutamatergic subpopulation. Conditionally deleting Pten in Ago2-deficient neurons restored Akt2 phosphorylation as well as postnatal development and survival. Several mutations in AGO2 impair small RNA silencing and are associated with Lessel-Kreienkamp syndrome, a neurodevelopmental disorder. When expressed in a neuronal cell line, these human AGO2 loss-of-function variants failed to suppress PTEN, resulting in attenuated PI3K-Akt signaling, further indicating that dysregulation of Ago2 function may contribute to both impaired development and neurological disorders. Together, these results identify Ago2 as central to the engagement of neurons with blood vessels in the developing brain.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Argonaute Proteins
|2 NLM Chemicals
650 _ 7 |a PTEN Phosphohydrolase
|0 EC 3.1.3.67
|2 NLM Chemicals
650 _ 7 |a Ago2 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Reln protein, mouse
|0 EC 3.4.21.-
|2 NLM Chemicals
650 _ 7 |a Reelin Protein
|2 NLM Chemicals
650 _ 7 |a RELN protein, human
|0 EC 3.4.21.-
|2 NLM Chemicals
650 _ 7 |a Pten protein, mouse
|0 EC 3.1.3.67
|2 NLM Chemicals
650 _ 7 |a MicroRNAs
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins c-akt
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Phosphatidylinositol 3-Kinases
|0 EC 2.7.1.-
|2 NLM Chemicals
650 _ 7 |a AGO2 protein, human
|2 NLM Chemicals
650 _ 7 |a Glutamic Acid
|0 3KX376GY7L
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Argonaute Proteins: metabolism
|2 MeSH
650 _ 2 |a Argonaute Proteins: genetics
|2 MeSH
650 _ 2 |a PTEN Phosphohydrolase: metabolism
|2 MeSH
650 _ 2 |a PTEN Phosphohydrolase: genetics
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Reelin Protein
|2 MeSH
650 _ 2 |a MicroRNAs: metabolism
|2 MeSH
650 _ 2 |a MicroRNAs: genetics
|2 MeSH
650 _ 2 |a Signal Transduction
|2 MeSH
650 _ 2 |a Blood-Brain Barrier: metabolism
|2 MeSH
650 _ 2 |a Proto-Oncogene Proteins c-akt: metabolism
|2 MeSH
650 _ 2 |a Proto-Oncogene Proteins c-akt: genetics
|2 MeSH
650 _ 2 |a Phosphatidylinositol 3-Kinases: metabolism
|2 MeSH
650 _ 2 |a Phosphatidylinositol 3-Kinases: genetics
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Glutamic Acid: metabolism
|2 MeSH
700 1 _ |a Yeh, Yu-Te
|0 0000-0001-7968-6081
|b 1
700 1 _ |a Li, Yunxiao
|0 0009-0006-6992-9098
|b 2
700 1 _ |a Liu, Xiaoxuan
|b 3
700 1 _ |a Ghosh, Adhideb
|0 0000-0002-5160-4571
|b 4
700 1 _ |a Hinte, Laura C
|0 0000-0002-4226-0009
|b 5
700 1 _ |a Ku, Min-Chi
|0 0000-0003-0963-2461
|b 6
700 1 _ |a Rathjen, Thomas
|b 7
700 1 _ |a Niendorf, Thoralf
|0 0000-0001-7584-6527
|b 8
700 1 _ |a Yu, Guoxing
|0 0000-0002-5194-8614
|b 9
700 1 _ |a Jia, Shiqi
|0 0000-0001-8595-9314
|b 10
700 1 _ |a Kononenko, Natalia L
|b 11
700 1 _ |a Hermann, Andreas
|0 P:(DE-2719)2811732
|b 12
700 1 _ |a Luo, Jiankai
|0 0000-0001-5169-3095
|b 13
700 1 _ |a Lin, Juntang
|0 0000-0001-9300-1771
|b 14
700 1 _ |a von Meyenn, Ferdinand
|0 0000-0001-9920-3075
|b 15
700 1 _ |a Yan, Xin
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Poy, Matthew N
|0 0000-0002-4904-2426
|b 17
773 _ _ |a 10.1126/scisignal.adl6745
|g Vol. 18, no. 875, p. eadl6745
|0 PERI:(DE-600)2417226-1
|n 875
|p eadl6745
|t Science signaling
|v 18
|y 2025
|x 1945-0877
856 4 _ |u https://pub.dzne.de/record/277315/files/DZNE-2025-00378_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/277315/files/DZNE-2025-00378_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:277315
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI SIGNAL : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b SCI SIGNAL : 2022
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1511100
|k AG Hermann
|l Translational Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1511100
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21